U.S. Anticoagulant Reversal Drugs Market Size & Outlook
U.S. anticoagulant reversal drugs market, 2016-2027 (US$M)
Related Markets
U.S. anticoagulant reversal drugs market highlights
- The U.S. anticoagulant reversal drugs market generated a revenue of USD 246.8 million in 2020 and is expected to reach USD 576.8 million by 2027.
- The U.S. market is expected to grow at a CAGR of 12.9% from 2021 to 2027.
- In terms of segment, idarucizumab was the largest revenue generating product type in 2020.
- Andexanet Alfa is the most lucrative product type segment registering the fastest growth during the forecast period.
Anticoagulant reversal drugs market data book summary
| Market revenue in 2020 | USD 246.8 million |
| Market revenue in 2027 | USD 576.8 million |
| Growth rate | 12.9% (CAGR from 2020 to 2027) |
| Largest segment | Idarucizumab |
| Fastest growing segment | Andexanet Alfa |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Prothrombin Complex Concentrates, Phytonadione (Vitamin K), Andexanet Alfa, Idarucizumab, Protamine |
| Key market players worldwide | AstraZeneca PLC, Boehringer Ingelheim, CSL Ltd, Bausch Health Companies Inc, Dr Reddy's Laboratories Ltd ADR, Fresenius SE & Co KGaA, Octapharma AG, AMAG Pharmaceuticals, SGPharma, Alps Pharmaceutical Industry Co |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.8% of the global anticoagulant reversal drugs market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. anticoagulant reversal drugs market is projected to lead the regional market in terms of revenue in 2027.
- Canada is the fastest growing regional market in North America and is projected to reach USD 91.4 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anticoagulant Reversal Drugs Market Scope
Anticoagulant Reversal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. anticoagulant reversal drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anticoagulant reversal drugs market will help companies and investors design strategic landscapes.
Idarucizumab was the largest segment with a revenue share of 35.9% in 2020. Horizon Databook has segmented the U.S. anticoagulant reversal drugs market based on prothrombin complex concentrates, phytonadione (vitamin k), andexanet alfa, idarucizumab, protamine covering the revenue growth of each sub-segment from 2016 to 2027.
Reasons to subscribe to U.S. anticoagulant reversal drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. anticoagulant reversal drugs market databook
-
Our clientele includes a mix of anticoagulant reversal drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. anticoagulant reversal drugs market, including forecasts for subscribers. This country databook contains high-level insights into U.S. anticoagulant reversal drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. anticoagulant reversal drugs market size, by product type, 2016-2027 (US$M)
U.S. Anticoagulant Reversal Drugs Market Share, 2020 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
